Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piracetam + morpholinium methylthiazotate
- Development stage
- Unknown
- Lead developer
- Scientific-Medical Enterprise
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Tiopyram is a fixed-dose combination pharmaceutical product containing the nootropic agent piracetam and the metabolic antioxidant morpholinium methylthiazotate (also known as thiotriazoline). Developed and manufactured by the Scientific-Medical Enterprise (Radiks) in Uzbekistan, it is primarily used for the treatment of cerebrovascular disorders. Piracetam, a cyclic derivative of GABA, acts as a nootropic by modulating glutamatergic neurotransmission and improving neuronal plasticity and microcirculation. Morpholinium methylthiazotate provides antioxidant protection, stabilizes neuronal membranes, and improves energy metabolism under ischemic conditions. The combination is indicated for the management of ischemic stroke, recovery from hemorrhagic stroke, and chronic cerebral circulatory insufficiency (encephalopathy).
- Brand names
- TiopyramТиопирам
- Other names
- piracetam + thiotriazoline
02
Targets
GRIA2 (AMPA receptor subunit GluA2)
Beyond the preview
Go deeper on piracetam + morpholinium methylthiazotate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piracetam + morpholinium methylthiazotate.